In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

The downgrade in valuation during December was attributed to the initial disappointment from the NOVO Cagrisema data, which was seen as indicative of the demand for next-generation peptides.

GLP-1, or glucagon-like peptide-1 drugs, can help people lose weight by reducing their appetite and slowing digestion. The most prescribed GLP-1 drugs include Ozempic, Wegovy, Mounjaro, CagriSema ...

GLP-1s, which form the basis of Novo's Wegovy and rival Eli Lilly's Zepbound, work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors are now watching for ...

GLP-1s, which form the basis of Novo's Wegovy and rival Eli Lilly's Zepbound, work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors have now been eagerly ...

GLP-1s, which form the basis of Novo's Wegovy and rival Eli Lilly's Zepbound, work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors are now watching for ...

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. Pharma giants Novo Nordisk and Eli Lilly look to be the main benefactors of GLP ...